

**FASEB Summer Research Conference
Cytokines and Lipid Mediators
July 8-13, 1995
Saxtons River, Vermont**

Chair:

Charles N. Serhan, Ph.D.
Hematology-Oncology Division
Brigham and Women's Hospital and
Harvard Medical School
221 Longwood Avenue, LMRC 611
Boston, MA 02115
Tel. 617-732-5875

Advisory Committee:

K. Frank Austen, M.D.
Professor and Chairman
Department of Rheumatology
and Immunology
Brigham and Women's Hospital and
Harvard Medical School
SGMB 604
250 Longwood Avenue
Boston, MA 02115

Gerald Weissmann, M.D.
Division of Rheumatology
New York University Medical Center
550 First Avenue
New York, NY 10016

1991 FASEB Chairman:
Patrick Y-K. Wong, Ph.D.
Department of Cell Biology
University of Medicine and Dentistry
of New Jersey
2 Medical Center Drive
Stratford, NJ 08084

Vice-Chair:

Christina C. Leslie, Ph.D.
National Jewish Center for
Immunology and Respiratory Medicine
1400 Jackson Street
Denver, CO 80206

1993 FASEB Chairman:
W. Pruzanski, M.D., FRCPC, FACP, FACR
Inflammation Research Group
University of Toronto
The Wellesley Hospital
160 Wellesley St. East
Toronto, Ont., Canada M4Y 1J3

1993 FASEB Vice-Chair:
Robert C. Murphy, Ph.D.
National Jewish Center for Immunology
and Respiratory Medicine
Department of Pediatrics
1400 Jackson Street
Denver, CO 80206

1991 FASEB Chairman:
Dr. Robert Lewis
Syntex Corp.
3401 Hillview Avenue
P.O. Box 10850
Palo Alto, CA 94304-1397

FASEB Summer Research Conference on "Cytokines and Lipid Mediators"
July 8-13, 1995, Saxtons River, Vermont

Tentative Program:

1. Nine scientific sessions (Total of 45 presentations plus 3-4 keynote addresses = 48-49).
2. Duration of each session is 3 1/2 hours.
3. Each session composed of ~5 presentations, each 20 min. with 5 min discussion and one coffee break of 15 min. Time will be regulated by chairpersons.
4. The opening address on the first 2 or 3 days will be denoted as keynote lectures.
5. Sessions will be chaired by 2 co-speakers (no moderators).

** Chairpersons will lead discussions at the end of each evening session and also highlight poster presentations ("guided tour style") for general discussion.

Suggested scholarly address to open the daily sessions:

Keynotes

Confirmed
availability

+	Peter Henson, Ph.D. Pediatrics National Jewish Center 1400 Jackson St., Room F305 Denver, CO 80206	Regulation of eicosanoid production in inflammatory cells
	Peter Elsbach, M.D. Dept. of Medicine New York University School of Medicine 550 First Avenue New York, NY 10016-6402	Regulation of activity in leukocyte function
+	Peter Libby, M.D. Dept. Pathology Brigham and Women's Hospital 221 Longwood Avenue Boston, MA 02115	Cytokines and lipid mediators in vascular disease
+	Marco Baggiolini, M.D. Theodor Kocher Institute University of Bern CH-3000 Bern 9 Switzerland	Interleukin-8 and other chemokines: A new understanding of leukocyte recruitment

FASEB Summer Research Conference on "Cytokines and Lipid Mediators"
July 8-13, 1995, Saxtons River, Vermont

Tentative Program

I. Molecular Biology of Enzymes in Lipid Mediators

Confirmed
availability

- | | | |
|---|---|---|
| + | 1. <u>Chair:</u>
Jesper Haeggström, M.D., Ph.D.
Karolinska Institutet | Mutagenesis of LTA ₄ hydrolase
and functional implications |
| + | 2. <u>Co-Chair:</u>
William L. Smith, Ph.D.
Michigan State University | Regulation of Cox-1 and Cox-2 |
| + | 3. Kenneth K. Wu, M.D.
University of Texas at Houston | Localization of TX synthetase |
| + | 4. Charles Mark Ensor, Ph.D.
University of Kentucky | Structure-function relationships of
NAD ⁺ -dependent 15-hydroxyprostaglandin
dehydrogenase |
| | 5. Shozo Yamamoto, M.D.
Tokushima University (Japan) | Distribution and expression of
12-lipoxygenase |
| + | 6. Olle Rådmark, M.D.
Karolinska Institutet | 5-LO mutagenesis and structure |
| + | 7. Roy Soberman, M.D.
Massachusetts General Hospital | Molecular basis of the transmembrane
movement of bioactive lipids |

II. Regulation of Inflammatory Processes

- | | | |
|---|--|---|
| + | 1. <u>Co-Chair:</u>
Michael P. Bevilacqua, M.D., Ph.D.
University of California, San Diego | Role of selectins in inflammation:
Endothelial cell activation and
selectin display |
| + | 2. <u>Co-Chair:</u>
James Madara, M.D.
Brigham and Women's Hospital | Pathobiology of epithelial-PMN interactions |
| | 3. Dr. M. Laurie Phillips
CYTEL Corporation | Selectin-carbohydrate interactions
in PMN transmigration |
| + | 4. Tucker Collins, M.D., Ph.D.
Brigham and Women's Hospital | Activation of NFκB in endothelial
cells and cytokine regulation |
| + | 5. Bruce N. Cronstein, M.D.
New York University Med. Ctr. | Inhibitors of PMN-endothelial
interactions |
| + | 6. Dr. Kenneth V. Honn
Wayne State University | Regulation of integrins by mono-HETEs
in platelet-endothelial interactions |

FASEB Summer Research Conference on "Cytokines and Lipid Mediators"
July 8-13, 1995, Saxtons River, Vermont

III. Cytokine Receptors and Function

- | | | |
|---|--|---|
| + | 1. Marina Pretolani, Ph.D.
INSERM U285
Institut Pasteur (Paris) | Cytokines and experimental
bronchopulmonary allergy |
| + | 2. H.H. Tai, Ph.D.
University of Kentucky | Regulation of interleukin-1 stimulated
prostaglandin synthesis by
interferons and interleukin-4 |
| + | 3. Dr. Paul H. Naccache
Le Centre Hospitalier de
l'Université Laval (Quebec) | Cytokines and signaling in
neutrophils |
| + | 4. Elliott Sigal, M.D., Ph.D.
Syntex Discovery Research | Cytokine regulation of 15-lipoxygenase
expression |
| * | 5. Open slot | "Breaking news" |
| * | 6. Open slot | "Breaking news" |

IV. Disease Models and Tissue Injury

- | | | |
|---|--|--|
| + | 1. <u>Co-Chair:</u>
Giora Z. Feuerstein, M.D.
SmithKline Beecham | Cytokines in pulmonary microvascular
injury and ARDS |
| + | 2. Allen M. Lefer, Ph.D.
Jefferson Medical College | Selectins as mediators of
reperfusion injury |
| + | 3. Dr. Sven-Erik Dahlén
Karolinska Institutet
(Stockholm) | Asthma: The role of leukotrienes
and 5-LO inhibitors |
| | 4. Johan Raud, M.D., Ph.D.
Karolinska Institutet
(Stockholm) | Microcirculatory events triggering
cell-cell interactions |
| + | 5. H. Daniel Perez, M.D.
Berlex Biosciences | Role of chemokines in multiple
sclerosis |

*To be selected from interested participants by conference chair.

FASEB Summer Research Conference on "Cytokines and Lipid Mediators"
July 8-13, 1995, Saxtons River, Vermont

V. Lipases in Mediator Release

- | | | |
|---|--|---|
| + | 1. <u>Chair:</u>
W. Pruzanski, M.D.
University of Toronto | Endogenous modulators of sPLA ₂ |
| + | 2. <u>Co-Chair:</u>
John D. Sharp, Ph.D.
Lilly Research Laboratories | PLA ₂ structure and catalysis |
| + | 3. Ruth M. Kramer, Ph.D.
Lilly Research Laboratories | Human platelet phospholipases A ₂ |
| + | 4. James D. Clark, Ph.D.
Genetics Institute | The role of the Ca ²⁺ -dependent lipid-binding domain in the regulation of cPLA ₂ |
| + | 5. John H. Exton, M.D., Ph.D.
Vanderbilt University School of Med. | Regulation of signalling phospholipases |
| + | 6. Peter Vadas, M.D.
Wellesley Hospital (Toronto) | Regulation of secretory PLA ₂ activity in septic shock |

VI. Eicosanoids in Cell Function

- | | | |
|---|--|---|
| + | 1. <u>Co-Chair:</u>
Jilly F. Evans, Ph.D.
Merck Frosst Centre/Canada | The role of FLAP in leukotriene biosynthesis |
| + | 2. <u>Co-Chair:</u>
Randy L. Bell, Ph.D.
Abbott Laboratories | Design of 5-LO inhibitors and their therapeutic utility |
| + | 3. Frank Fitzpatrick, Ph.D.
University of Colorado
Health Sciences Ctr. | Cellular enzymology of leukotriene biosynthesis |
| + | 4. Patrick Y-K. Wong, Ph.D.
University of Medicine and Dentistry
of New Jersey | Regulation of LTB ₄ EET generation |
| + | 5. Cecil R. Pace-Asciak, Ph.D.
Hospital for Sick Children
(Toronto) | Hepoxilins in cell activation |

FASEB Summer Research Conference on "Cytokines and Lipid Mediators"
July 8-13, 1995, Saxtons River, Vermont

VII. Lipid Mediators, Receptors and Signal Transduction

- | | | |
|---|--|---|
| + | 1. <u>Co-Chair:</u>
Takao Shimizu, M.D.
The University of Tokyo | Platelet-activating factor and
cellular responses |
| + | 2. <u>Co-Chair:</u>
Robert W. Egan, Ph.D.
Schering-Plough Research Inst. | Update on PLD activation and
PA generation |
| + | 3. Craig Gerard, M.D., Ph.D.
Children's Hospital (Boston) | PAF receptors, structure-
activity relationships |
| + | 4. Norma Gerard, Ph.D.
Children's Hospital (Boston) | PAF signal transduction and
intracellular messengers |
| + | 5. Shuh Narumiya, M.D., Ph.D.
Kyoto University | Prostanoid receptors in immune system
and cells |
| + | 6. Stefano Fiore, M.D.
Brigham and Women's Hospital | LX receptors, regulation and
signal transduction |

VIII. Cell-Cell Interactions

- | | | |
|---|---|---|
| + | 1. <u>Co-Chair:</u>
Pierre Borgeat, Ph.D.
Le Centre Hospitalier de
l'Université Laval (Quebec) | Inhibitory and stimulatory mechanisms
of regulation of leukotriene synthesis
neutrophils |
| + | 2. <u>Co-Chair:</u>
Robert C. Murphy, Ph.D.
National Jewish Center for
Immunology and Resp. Med. | Leukotriene A ₄ synthase activity in the
isolated human eosinophil and neutrophil |
| + | 3. Hans E. Classen, M.D., Ph.D.
Karolinska Institutet
(Stockholm) | Lymphocyte-5-LO activation and
its impact in lymphoid tissue |
| + | 4. Hugh Brady, M.D., Ph.D.
Veterans Affairs Medical Center
(West Roxbury, MA) | LO products in the regulation of
PMN-endothelial cell interactions |
| + | 5. Timothy D. Bigby, M.D.
Univ. of California, San Diego | Monocyte-lymphocyte interactions
and the generation of LTB ₄ and HETEs |
| + | 6. Beverly Barton, Ph.D.
Schering-Plough Research Inst. | Role of IL-6 in animal models |

FASEB Summer Research Conference on "Cytokines and Lipid Mediators"
July 8-13, 1995, Saxtons River, Vermont

IX. Regulation of Lipid Mediator Production and Signal Transduction

Part A:

- | | | |
|---|--|--|
| + | 1. <u>Co-Chair:</u>
Leslie R. Ballou, Ph.D.
Veterans Affairs Medical Center
(Memphis, TN) | Sphingolipids and the regulation of
cytokine-mediated eicosanoid biosynthesis |
| + | 2. Stephen Prescott, M.D.
University of Utah School of Medicine | DG-lipase, PAF-regulating enzymes |
| + | 3. Yusuf A. Hannun, M.D.
Duke University Medical Center | Ceramide: A tumor suppressor lipid |

Break

Part B: Inhibitor Design in Signal Transduction

- | | | |
|---|---|--|
| + | 4. Alan J. Lewis, Ph.D.
Signal Pharmaceuticals Inc. | Targeting transcription factors to
modulate cytokine production |
| + | 5. Eduardo G. Lapetina, Ph.D.
Wellcome Research Laboratories | G-protein coupling in platelet
activation |

FASEB Summer Research Conference on "Cytokines and Lipid Mediators"
July 8-13, 1995, Saxtons River, Vermont

Open Slots: To be filled after announcement of the conference.

Session III

Open topic

Session III

Open topic

Speaker list and topics will be printed and circulated before the meeting. These will be distributed more than 12 months in advance.

Following announcements in *Science*, *J.B.C.*, *Cell*, etc., the listed Chairpersons will be contacted by speakers with "new/hot info" to present in one of 2-3 open slots in the outline designated in Session II. We trust that this will insure delivery of timely new results as well as engage those interested scientists who may not have been considered by this committee.

Poster sessions:

1. Poster submissions will be encouraged in the meeting announcements and circulars.
2. The poster sessions will be strategically located to trigger and ensure maximum discussion prior to dinner and other designated gatherings of the group.